Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (738)	9/16/2003 11:12:12 AM
From: Icebrg	Read Replies (1) \| Respond to of 2240

GENMAB ACHIEVES MILESTONE IN AMGEN LICENSE AGREEMENT Summary: Genmab has achieved a milestone with Amgen by delivering an antibody that targets the IL15 receptor. Copenhagen, Denmark; September 16, 2003 – Genmab A/S (CSE: GEN) announced today that it has achieved a milestone in its license agreement with Amgen by delivering an antibody that targets the IL15 receptor. Under the terms of the agreement, Genmab will receive a milestone payment of USD 500,000. "We are pleased to reach a milestone in our agreement with Amgen," said Lisa N. Drakeman, Ph. D. Chief Executive Officer of Genmab.